Lack of overall survival benefit for aromatase inhibitors examined
Cumulative toxicity may explain the low overall survival benefit of aromatase inhibitors (AIs) despite improvements in breast cancer-free survival, according to a recent meta-analysis (Journal of the National Cancer Institute 2011;103:1).
Researchers analysed data from seven randomised trials including 30,023 postmenopausal women with early-stage breast cancer. They found that, compared with tamoxifen, the use of AIs as first-line adjuvant treatment was associated with an increased risk of cardiovascular disease and bone fractures, and a reduced risk of venous thrombosis and endometrial cancer.
Citation: Clinical Pharmacist URI: 11083349
Recommended from Pharmaceutical Press